Chemometec — September 2025
-
Chemometec har fået hævet sit kursmål til 690 kr. fra 640 kr. hos DNB https://proinvestor.com/investornyt/1359928/chemometec-har-faet-haevet-sit-kursmal-til-690-kr-fra-640-kr-hos-dnb
-
Ja, det ser ud til, at ChemoMetecs årsregnskab for 2024/2025 offentliggøres i dag – den 11. september 2025. Ifølge virksomhedens Investor Relations-side er der også planlagt en konference opkald i morgen, den 12. september, hvor ledelsen vil gennemgå resultaterne.
-
ChemoMetec A/S Releases 2025/26 Guidance: Revenue Expected to Rise to DKK 545-565 Million; EBITDA to Increase to DKK 295-315 Million
19:12
ChemoMetec A/S has released its annual report for the 2024/25 financial year
and provided guidance for the 2025/26 period. The company reported a revenue
of DKK 495.6 million for 2024/25. For the upcoming financial year 2025/26,
ChemoMetec anticipates revenue to be in the range of DKK 545-565 million. In
terms of EBITDA, the company achieved DKK 258.0 million -
ChemoMetec A/S Reports 22% Revenue Growth to DKK 495.6 Million and 39% Increase in Profit to DKK 186.4 Million for 2024/25
19:16
ChemoMetec A/S has announced its financial results for the 2024/25 financial
year. The company reported a 22% increase in revenue, reaching DKK 495.6
million. The growth was attributed to an increase in sales of instruments,
consumables, and services. The company's EBITDA rose by 39% to DKK 258.0
million, with the EBITDA margin improving to 52% from 46% in the previous -
46% in the previous
year. The profit for the year increased by DKK 50.1 million, amounting to DKK
186.4 million. The Board of Directors has proposed a dividend of DKK 7.0 per
share, resulting in a total dividend payout of DKK 121.8 million for the
2024/25 financial year. Looking ahead, ChemoMetec expects revenue for the
2025/26 financial year to be in the range of DKK 545-565 million, with an
anticipated EBITDA range of DKK 295-315 million. The launch of the new
XcytoMatic products is reported -
products is reported to be proceeding as planned.
-
Ingen “slinger” i det regnskab og omsætning/EBITDA forventes at vokse pænt igen næste år…..om det så er nok til at tilfredsstille markedet må vi se i morgen
-
Chemometec leverer stor vækst og stærk prognose trods tiltagende usikkerhed https://proinvestor.com/investornyt/1360760/chemometec-leverer-stor-vaekst-og-staerk-prognose-trods-tiltagende-usikkerhed
-
Godt nok et voldsomt fald i shortere i ChemoMetec det sidste års tid
Fra omkring 10% sidste sommer til omkring 1% i dag. Nogen har godt nok skyndt sig at komme ud, da de fuldstændig havde fejlbedømt selskabet https://www.zirium.dk/short-watch-details?code=DK0060055861 -
Chemometec får højere kursmål hos SEB https://proinvestor.com/investornyt/1361380/chemometec-far-hojere-kursmal-hos-seb
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind